Clinical trials: Heart Failure, Reduced Ejection Fraction
Heart Failure, Heart Failure, Systolic
COmparing arNi and Ace For Improving Erectile Dysfunction in mEN With reduCed Ejection Fraction Heart Failure
The purpose of this study was to determine the effect of sacubitril/valsartan (LCZ696) vs. Enalapril on improvement in erectile function and ability in male patients with chronic heart failure with reduced ejection fraction and…
- Conditions
- Heart Failure, Heart Failure, Systolic, Erectile Dysfunction
- Trial name
- CONFIDENCE-HF (NCT03917459)
- Testing
- LCZ696, Enalapril
- Where
- 13 sites in Germany
- Volunteers
- 27 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure With Preserved Ejection Fraction
Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure.
This is an international, multicentre, parallel-group, event-driven, randomised, double-blind, placebo-controlled study in HFpEF patients, evaluating the effect of dapagliflozin 10 mg versus placebo, given once daily in addition…
- Trial name
- DELIVER (NCT03619213)
- Testing
- Dapagliflozin
- Where
- 348 sites in United States, Argentina and 18 more
- Volunteers
- 6,263 people
- Sponsor
- AstraZeneca
Heart Failure and Reduced Ejection Fraction
Study of Effects of Sacubitril/Valsartan vs. Enalapril on Aortic Stiffness in Patients With Mild to Moderate HF With Reduced Ejection Fraction
To determine whether treatment with sacubitril/valsartan provides a superior effect on aortic characteristic impedance compared to enalapril in patients with heart failure and reduced ejection fraction (left ventricular ejection…
- Trial name
- EVALUATE-HF (NCT02874794)
- Testing
- LCZ696 (sacubitril/valsartan), Enalapril
- Where
- 81 sites in United States
- Volunteers
- 465 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Systolic Heart Failure
Medical Arm of the Interagency Registry for Mechanically Assisted Circulatory Support
Medamacs is a prospective, observational study of ambulatory patients with advanced heart failure. The study enrolls patients who have not yet received a Left Ventricular Assist Device (LVAD) but who receive their care at a…
- Trial name
- Medamacs (NCT01932294)
- Where
- 11 sites in United States
- Volunteers
- 171 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Heart Failure With Reduced Ejection Fraction, HIV Infections
Heart Failure Polypill at a Safety Net Hospital
A novel four-drug regimen for heart failure with reduced ejection fraction (HFrEF) extends patients' life expectancy by an average of 6 years compared to traditional therapies, in addition to improving quality of life.
- Trial name
- NCT06029712
- Testing
- Heart failure polypill, Control Rx
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of California, San Francisco
Heart Failure
Effect of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction
This was a randomized, double-blinded, placebo-controlled, multiple-dose study in subjects with stable heart failure (HF) with reduced ejection fraction (HFrEF).
- Trial name
- NCT02788747
- Testing
- 4 mg elamipretide, 40 mg elamipretide
- Where
- 15 sites in Italy, Netherlands and 1 more
- Volunteers
- 71 people
- Sponsor
- Stealth BioTherapeutics Inc.
Chronic Heart Failure With Reduced Ejection Fraction
Exercise Capacity Study of LCZ696 vs. Enalapril in Patients With Chronic Heart Failure and Reduced Ejection Fraction.
The purpose of the study was to determine the effect of LCZ696 vs. enalapril on improvement of exercise capacity in patients with chronic heart failure with reduced ejection fraction.
- Trial name
- NCT02768298
- Testing
- LCZ696, Enalapril
- Where
- 34 sites in Germany
- Volunteers
- 201 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Congestive, Myocardial Infarction
IMPROVE HF: Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting
The purpose of this study is to characterize current management of patients with either heart failure or prior myocardial infarction and left ventricular dysfunction and to assess the effect of education, specific clinical…
- Conditions
- Heart Failure, Congestive, Myocardial Infarction, Ventricular Dysfunction, Left
- Trial name
- IMPROVE-HF (NCT00303979)
- Where
- 144 sites in United States
- Volunteers
- 34,810 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure
Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction
Ertugliflozin to Reduce Arrhythmic Burden in ICD/CRT patientS (ERASe-Trial) - a Phase III Study
The recent study is planned to investigate the impact of Ertugliflozin on total burden of ventricular arrhythmias. Further objectives will be number of therapeutic interventions of implanted devices, atrial fibrillation, heart…
- Conditions
- Heart Failure With Reduced Ejection Fraction, Heart Failure With Mid Range Ejection Fraction, Implantable Cardioverter-Defibrillators, Cardiac Resynchronization Therapy
- Trial name
- ERASE (NCT04600921)
- Testing
- Ertugliflozin 5 mg
- Where
- 8 sites in Austria
- Volunteers
- 55 people
- Sponsor
- Medical University of Graz
Non-ischemic Cardiomyopathy, Systolic Heart Failure (NYHA II-III)
Safety and Efficacy of Doxycycline in Patients With Non-Ischemic Cardiomyopathy
Non-ischemic cardiomyopathy and heart failure are highly influenced by the presence of systemic inflammation. Doxycycline is a FDA-approved drug to treat bacterial infections which also shows powerful anti-inflammatory effects.
- Trial name
- DOXY-HF (NCT01935622)
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Virginia Commonwealth University
Heart Failure
This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms
The primary objective of the study is to evaluate the effect of empagliflozin 10 mg versus placebo on exercise ability using the 6 minute walk test in patients with chronic HF with reduced ejection fraction (LVEF ≤ 40%) Secondary…
- Trial name
- NCT03448419
- Testing
- Empagliflozin
- Where
- 109 sites in United States, Australia and 9 more
- Volunteers
- 312 people
- Sponsor
- Boehringer Ingelheim
Hyperkalemia
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
- Trial name
- DIAMOND (NCT03888066)
- Testing
- Patiromer
- Where
- 415 sites in United States, Argentina and 19 more
- Volunteers
- 1,195 people
- Sponsor
- Vifor Pharma, Inc.
Chronic Heart Failure With Reduced Ejection Fraction
randOmized stUdy Using acceleromeTry to Compare Sacubitril/valsarTan and Enalapril in Patients With Heart Failure
The purpose of this randomized, actively controlled, double-blind study with prospective data collection was to assess differences between sacubitril/valsartan versus enalapril in increasing exercise capacity and non-sedentary…
- Trial name
- OUTSTEP-HF (NCT02900378)
- Testing
- LCZ696 (Sacubitril/Valsartan), Enalapril
- Where
- 119 sites in Belgium, Bulgaria and 17 more
- Volunteers
- 621 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Sick Sinus Syndrome, Complete Heart Block
Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.
The number of cardiac implantable electronic devices (CIEDs) implanted each year has grown rapidly over the past two decades. CIED infections, defined as infections involving the generator implant site (pocket) and/or…
- Conditions
- Sick Sinus Syndrome, Complete Heart Block, Syncope, Chronic Systolic Heart Failure
- Trial name
- ENVELOPE (NCT02809131)
- Testing
- polymixin/bacitracin, cephalexin, or levofloxacin, or clindamycin, Saline
- Where
- United States
- Volunteers
- 1,010 people
- Sponsor
- Vanderbilt University Medical Center
Hyperkalaemia, Heart Failure With Reduced Ejection Fraction
Study to Assess Efficacy and Safety of SZC for the Management of High Potassium in Patients With Symptomatic HFrEF Receiving Spironolactone
The main objective of this study is to evaluate the efficacy of SZC as compared with placebo in keeping potassium levels within the normal range (3.5-5.0 mEq/L) while on spironolactone ≥25 mg daily without assistance of rescue…
- Trial name
- REALIZE-K (NCT04676646)
- Testing
- Sodium zirconium cyclosilicate, Spironolactone
- Where
- 89 sites in United States, Brazil and 6 more
- Volunteers
- 366 people
- Sponsor
- AstraZeneca
Heart Failure
Effects of Aliskiren, Ramipril, and the Combination on Levels of Angiotensin II in Patients With Decompensated Systolic Heart Failure
In addition to the blood pressure lowering effects of aliskiren, it may have beneficial effects on blocking the so called RAAS (renin-angiotensin-aldosterone system) at the tissue level.
- Trial name
- ESCAPE-SHF (NCT00923156)
- Testing
- aliskiren, ramipril
- Where
- 16 sites in Germany, Poland and 1 more
- Volunteers
- 123 people
- Sponsor
- Novartis Pharmaceuticals
Acute Heart Failure With Reduced Ejection Fraction
A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction
The purpose of this study is to evaluate the safety, pharmacokinetics, and effect on cardiac function of intravenous APD418 in adult participants with heart failure with reduced ejection fraction (HFrEF).
- Trial name
- NCT05139615
- Testing
- APD418
- Where
- 21 sites in United States, Germany and 3 more
- Volunteers
- 22 people
- Sponsor
- Pfizer
Heart Failure; With Decompensation
Compression Wraps as Adjuvant Therapy in Management of Acute Systolic Heart Failure
There will be two populations in this study: control group, and intervention group. These groups will undergo propensity matching to account for confounders and minimize selection bias.
- Trial name
- CATAS-HF (NCT04095416)
- Testing
- ACE compression wrap
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Henry Ford Health System
Systolic Heart Failure, Cardiac Resynchronization Therapy
ECG for Programming in CRT
Patients with heart failure and left bundle branch block benefit from Cardiac Resynchronization Therapy (CRT) that delivers pacing from right ventricle (RV) and left ventricle (LV) synchronously, resulting in electrical…
- Conditions
- Systolic Heart Failure, Cardiac Resynchronization Therapy, Electrocardiography
- Trial name
- EPIC (NCT03936608)
- Testing
- Programming individualized RV-LV pacing offset to optimize ECG, Nominally programming CRT device without RV-LV offset
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Heart Failure, Heart Failure Hospitalization
Teach-Back Discharge Education to Improve Self-Care and Reduce 30-Day Readmissions in Heart Failure Patients
This study aimed to improve how patients with heart failure understand and manage their condition after leaving the hospital. Many heart failure patients are readmitted within 30 days due to confusion about their discharge…
- Conditions
- Heart Failure, Heart Failure Hospitalization, Readmission, Hospital
- Trial name
- NCT07280208
- Testing
- Teach-Back Discharge Education
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Nova Southeastern University